AU2880595A - Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses - Google Patents

Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses

Info

Publication number
AU2880595A
AU2880595A AU28805/95A AU2880595A AU2880595A AU 2880595 A AU2880595 A AU 2880595A AU 28805/95 A AU28805/95 A AU 28805/95A AU 2880595 A AU2880595 A AU 2880595A AU 2880595 A AU2880595 A AU 2880595A
Authority
AU
Australia
Prior art keywords
alleviation
treatment
viruses
immunodeficiency
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU28805/95A
Inventor
Bo Arne Hofmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2880595A publication Critical patent/AU2880595A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU28805/95A 1994-07-06 1995-07-05 Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses Abandoned AU2880595A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DK810/94 1994-07-06
DK81094 1994-07-06
DK1447/94 1994-12-20
DK144794 1994-12-20
PCT/DK1995/000286 WO1996001107A1 (en) 1994-07-06 1995-07-05 Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses

Publications (1)

Publication Number Publication Date
AU2880595A true AU2880595A (en) 1996-01-25

Family

ID=26064706

Family Applications (1)

Application Number Title Priority Date Filing Date
AU28805/95A Abandoned AU2880595A (en) 1994-07-06 1995-07-05 Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses

Country Status (2)

Country Link
AU (1) AU2880595A (en)
WO (1) WO1996001107A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889038A (en) 1996-03-20 1999-03-30 Children's Hospital Methods and products for treating diarrhea and scours: use of clotrimazole and related aromatic compounds
JP4376970B2 (en) 1996-03-20 2009-12-02 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ Triarylmethane compounds for sickle cell disease
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
AU4537300A (en) * 1999-05-12 2000-12-05 Neurosearch A/S Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction
AT409084B (en) * 2000-07-13 2002-05-27 Ledochowski Maximilian Dr ANTIMYCOTIC MEDICINAL PRODUCT
ITMI20021860A1 (en) * 2002-08-28 2004-02-29 Scalia Antonio Cassar USE OF TRIPTANS AS ANTI-VIRAL AGENTS.
JP5932636B2 (en) * 2009-05-05 2016-06-08 ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイテッド Therapeutic compound
EP3609521A4 (en) 2017-04-14 2021-06-16 University of Massachusetts Targeting cell tropism receptors to inhibit cytomegalovirus infection
WO2019088926A1 (en) * 2017-11-01 2019-05-09 National University Of Singapore Use of serotonergic drugs to treat virus-induced thrombocytopenia

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06503816A (en) * 1990-09-04 1994-04-28 マイルズ　インコーポレイテッド Regulation of T cell proliferation through a novel 5HT1a receptor

Also Published As

Publication number Publication date
WO1996001107A1 (en) 1996-01-18

Similar Documents

Publication Publication Date Title
EP0831873A4 (en) The treatment of hiv and other viral infections using combinatory therapy
IL143512A (en) Azabicycloalkanes, pharmaceutical compositions comprising same and use thereof for the manufacture of medicaments for the prevention or treatment of infection by immunodeficiency virus
CA2293470A1 (en) Benzimidazole derivatives
CA2072573A1 (en) Treatment of human retroviral infections with 2&#39;,3&#39;-dideoxyinosine
AU2880595A (en) Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses
AU2784792A (en) Human monoclonal antibodies to the cd4-binding domain of hiv, uses thereof and synergistic neutralization of hiv
AU5848794A (en) Multiple-gene mutants of human immunodeficiency virus (hiv) for vaccine use
AU4088697A (en) Postinfection human immunodeficiency virus (hiv) vaccination therapy
AU9173191A (en) Medicaments for the treatment of papillomavirus diseases
WO1999051256A3 (en) Use of l-glu-l-trp in the treatment of hiv infection
CA2189705A1 (en) Use of flupirtine for the prophylaxis and therapy of diseases associated with an impairment of the haematopoetic cell system
EE03514B1 (en) A combination of compounds for the treatment of HIV infection or AIDS, its use and a pharmaceutical composition
AU2880495A (en) Use of pharmaceutical agents for alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses
IL102815A (en) Pharmaceutical compositions for the treatment of infection caused by the human immunodeficiency virus
AU2229997A (en) Pharmaceutical compositions comprising natural human alpha-interferon
EP0316592A3 (en) 3&#39;-fluoro-2&#39;,3&#39;-dideoxyuridine, and its therapeutic application
CZ69695A3 (en) The use of non-nucleoside medicament against hiv for preparing a medicament for treating hiv-positive individuals
EP0655919A4 (en) Treatment of human viral infections.
CA2218553A1 (en) 2,4-dichlorobenzyl alcohol and amylmetacresol against hiv infection
AU696629B2 (en) Use of bradykinin antagonists for the preparation of medicaments for the treatment of virus diseases
WO2001030325A3 (en) Use of a bis-peroxovanadium compound for the treatment of immunosuppressed patients
CA2014884A1 (en) 5,11-dihydro-6h-pyrido[2,3-b][1,4]benzodiazepin-6-ones and -thiones and their use in the prevention or treatment of aids
WO1999038524A3 (en) Therapeutic administration of low density lipoprotein receptor for viral infections and immune regulation
ZA945418B (en) Method of inhibiting the replication of human immunodeficiency viruses (HIV) in HIV seropositive humans.
CA2088788A1 (en) Peptides that block human immunodeficiency virus infections and methods of use thereof